

Exceptional service in the national interest



Global Futures Biotechnology: A Bio-Empowered World

November 3rd, 2016

Presenters: Patricia Pacheco, Org 8114


Matthew Sumner, Org 8114

Contributors: Centers 100, 8100, Senior Scientists




Sandia National Laboratories is a multi-program laboratory managed and operated by Sandia Corporation, a wholly owned subsidiary of Lockheed Martin Corporation, for the U.S. Department of Energy's National Nuclear Security Administration under contract DE-AC04-94AL85000. SAND NO. 2011-XXXXP

What is Biotechnology?





Introduction to Topic

What is Biotechnology?



MICRONEEDLES DRUG PATCH



Introduction to Topic Sandia's Biotechnology Work

Sandia Protocells



(Photo by Randy Montoya)


Microneedle fluidic sensor



(Photo by Randy Montoya)

Computational enzyme design

Asparaginase enzyme



(Graphic by Juan
Vanegas)




(Photo by Randy
Montoya)

Peripheral Nerve Interfaces




(Photo by Randy Montoya)

Neural computing



(Photo by Frances Chance,
courtesy of Janelia Farm
Research Campus)

CO₂ Memzyme




Purified CO₂ at high transport rate
(http://www.sandia.gov/news/publications/lab_accomplishments/articles/2016/bioscience.html)

Sky Bridge



(Photo by Regina Valenzuela)

jbei Joint BioEnergy Institute



(Photo by Dino Vournas)

BaD_x




(Photo courtesy of
Melissa Finley)

(Photo by Thayne
Edwards)




SpinDx



(Photo by Randy Wong)

Biotech Primed for “Golden Age”




Global Futures theme:
*Potential of a networked,
platform-centric world*

**These elements are not unique
to biotechnology but seem to
be crossing critical thresholds.**

Accessibility of the Human Genome

Cost per Genome





Rapid pace makes it difficult to predict advances.

Understanding dynamics and expecting to be surprised may help.

BioBricks™ and Biohacking




>20,000 registered sequences



Gain of Function

Highly Transmissible




Highly Pathogenic

super-influenza


Natural evolution, research accident, hobbyist, or malicious actor

De novo synthesis of...

Novel, self-replicating bacteria cells with entirely manmade DNA



Infectious poliovirus from a test-tube



$C_{332,652}H_{492,388}N_{98,245}O_{131,196}P_{7,501}S_{2,340}$

Democratization of Biotechnology

Synbiota

Platform

RDP Standard


DNA Market

Blog

DNA Tinker Studio - \$1195



Rainbow Factory - \$295
DIY Incubator - \$125





KICKSTARTER


Improvements in cost, information, and collaboration lower barriers, support democratization, and unlock creativity (unpredictability).

Shifting Balance of Power


Shifts in power collectively lower influence of US Government over future of these technologies.



Convergence of Technologies





1980



2010


Nano-CRISPR



Examples of Convergence of Technologies

Gene Editing and Gene Drive


Targeting therapeutics both *in vivo* and *in utero* using nanotechnology and biochemistry



Malaria


Tissue Engineering

On-demand printing of new organs with the aid of novel materials science




Biocomputing

Supercomputing to understand the genome and vice-versa




Wearables and Implantables





Continuous monitoring of vitals and delivery of drugs in response using MEMS technology


- Rapid democratization requires new approaches
 - Technological superiority not viable
 - Reactive responses too late (esp. with traditional R&D cycle)
 - **Preparedness must coevolve with technology**
- Medical revolutions both address and cause national security concerns
 - 500-yr lifespan?
 - Only for the world's 1%?
- Biotech applications limited by concerns over poorly understood complex systems
 - Ecological effects
 - Optimized, but fragile, engineered species
 - Bioethics made real
 - Bio-intellectual property



Implications for National Security Human Engineering



Wearable
Augmented
Reality



Genetically
Enhanced
Senses

Genetically
Enhanced
Muscle
Growth



“Sputnik
moment”?


US policy?

Ethics?

- Biotechnology is experiencing rapid advances and significant convergence with other domains, leading to an apparently inevitable future in which it enables both the wondrous and the threatening.
- The spread of capabilities includes a broad set of international participants.
- Many advances are expected to offer dual-use capabilities, and the impact to the nation will be significant and largely unpredictable. A strategy of control is futile, so the US needs to emphasize anticipation, resilience and agility.

Closing thoughts

As R&D advances knowledge,
innovations can occur quickly.
The technology is waiting....



For you!!

Acknowledgements

- Matthew Sumner, Brandon Heimer, Patricia Pacheco, Todd West, George Backus, Thor Osborn, Cathy Ann Connelly, Wendell Jones, Tom Nelson
- SME Input: George Bachand, Cathy Branda, Jen Gaudioso, Carlos Gutierrez, Sheryl Hingorani, Dennis Imbro, Michael Nacht (UC Berkeley), Blake Simmons, and Anup Singh

QUESTIONS?

References

BACKUP SLIDES

Challenges of Oversight

- Society (and regulators) have difficulty keeping up with rapid pace of advances
- It may not be possible to regulate heavily democratized technologies
 - High standards for professionals, but hobbyists and malicious actors create challenges
- International variations in oversight may...
 - Drive research to less restrictive countries
 - Create asymmetries in capabilities
 - Render local standards ineffective
- If security-relevant capabilities are not domestic, US could be at the mercy of another nation
 - Biofuels, food, vaccines, drugs, ...



nature International weekly journal of science

Chinese scientists genetically modify human embryos

“A Chinese source familiar with developments in the field said that at least four groups in China are pursuing gene editing in human embryos.”

2003
Funding denied by USDA

2008
FDA receives application

2011
Research moved to Brazil



**“Error bars” on future states
encompass the miraculous and
the terrifying.**

